Artal Group S.A. Biocryst Pharmaceuticals Inc Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $539,197 - $804,042	67,909 New	67,909 $566,000
Q1 2018 May 10, 2018	SELL	$4.35 - $5.82 $2.18 Million - $2.91 Million	-500,000 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$4.16 - $5.33 $624,000 - $799,500	-150,000 Reduced 23.08%	500,000 $2.46 Million
Q3 2017 Nov 08, 2017	BUY	$4.1 - $5.97 $2.67 Million - $3.88 Million	650,000	650,000 $3.41 Million

285

171M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.62B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.